Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
Coherus is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Our colleagues are experts in analytical and process sciences, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities. Everyone at Coherus is committed to meeting the highest standards, inspiring our teammates, and achieving our goals.
Coherus was founded a decade ago to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
At Coherus, our employees are our most important asset. We have a dynamic and rewarding organizational culture that offers the opportunity to work with leading industry professionals who are dedicated to making a difference for patients. We are looking for individuals who see unlimited potential in themselves and are motivated by a continuous passion for breaking down barriers and expanding access to lifesaving therapeutics.
Coherus offers a competitive total rewards program comprised of various elements, including competitive base pay, short- and long-term incentives in the form of performance-based cash and equity, as well as health and wellness benefits that include
• Healthcare: Coherus pays 90% of premiums for medical, dental, and vision coverage for our
employees, their eligible spouses, dependents, and domestic partners.
• Health Savings and Flexible Spending Accounts
• Group Life, Disability, and Group Accident Insurance
• 401(k) with company match, and an Employee Stock Purchase Plan (ESPP)
• Paid Time Off (PTO)
• Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
In addition to providing attractive rewards packages, we encourage and support our employees to find the right balance of work and personal time. Coherus offers a variety of activities, perks, and holidays that encourage employees to have a healthy outlook, spend time outside of work with friends and family, and foster a productive and collaborative work environment. Our culture is one in which we challenge and support all our team members to do their best work.
For more information about Coherus, please check out: https://www.coherus.com/about-coherus/
271 articles about Coherus BioSciences
-
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
8/3/2020
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020.
-
Coherus BioSciences Announces New Employment Inducement Grants - July 17, 2020
7/17/2020
Coherus BioSciences, Inc., announced that effective July 16, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 53,000 shares of the common stock of the Company to four newly hired non-officer employees, with a per share exercise price of $18.30, the closing trading price on the grant date.
-
Coherus BioSciences to Report Second Quarter Financial Results on August 6th
7/16/2020
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020. Starting at 4:30 p.m. ET, Coherus’ management team will host a conference call to discuss financial results and provide a general business update. After releasing second quarter financial results, the Company will post them on the Coherus website at https:
-
Coherus BioSciences Announces New Employment Inducement Grants - June 19, 2020
6/19/2020
Coherus BioSciences, Inc., announced that effective June 18, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 93,000 shares of the common stock of the Company to seven newly hired non-officer employees, with a per share exercise price of $16.98, the closing trading price on the grant date.
-
Coherus BioSciences Reports First Quarter 2020 Financial Results
5/7/2020
Coherus BioSciences, Inc., reviewed corporate events and reported financial results for the quarter ended March 31, 2020.
-
Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference
5/4/2020
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at https://investors.coherus.com . About Coherus BioSciences, Inc. Coherus is a leading biosimilar company
-
Coherus BioSciences to Report First Quarter Financial Results on May 7th
4/22/2020
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020.
-
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
4/15/2020
Coherus BioSciences, Inc., announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering - April 14, 2020
4/14/2020
Coherus BioSciences, Inc., announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior subordinated notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact InsightsCOVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020
4/13/2020
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced preliminary unaudited revenue for UDENYCA® and net income for the quarter ended March 31, 2020
-
Coherus BioSciences Announces New Employment Inducement Grants - March 20, 2020
3/20/2020
Coherus BioSciences, Inc., announced that effective March 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 57,500 shares of the common stock of the Company to three newly hired non-officer employees, with a per share exercise price of $12.86, the closing trading price on the grant date.
-
United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand
3/5/2020
US-based supply chain mitigates coronavirus-related disruption risks
-
Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020
3/5/2020
Coherus BioSciences, Inc., announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m. ET, being held in Miami.
-
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
2/27/2020
Coherus BioSciences, Inc., reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2019.
-
Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference
2/26/2020
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. ET, being held in Boston.
-
Coherus BioSciences Announces New Employment Inducement Grants - Feb. 20, 2020
2/20/2020
Coherus BioSciences, Inc., announced that effective February 18, 2020, the compensation committee of the Company’s board of directors granted options to purchase 135,000 shares of the common stock of the Company to four newly hired non-officer employees, with a per share exercise price of $22.16, the closing trading price on the grant date.
-
Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th
2/6/2020
REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2019 financial results will be released after market close on Thursday, February 27, 2020.
-
Latham & Watkins Advises Coherus in a License Agreement to Acquire the Commercial Rights for Avastin® Biosimilar
1/22/2020
Coherus BioSciences, Inc. announced the Company has entered into a licensing agreement with Innovent Biologics, Co., Ltd.,, a leading biopharmaceutical company headquartered in China, to commercialize Innovent’s biosimilar candidate to Avastin® in the United States and Canada.
-
The biosimilar candidate, IBI305, completed a Phase III study in China and was granted Priority Review by that country’s National Medical Products Administration.
-
Chris Lehman Joins Avellino Labs As Chief Financial Officer
1/14/2020
Avellino Labs, global biotechnology and precision medicine innovators, announced that Chris Lehman has joined the company as Chief Financial Officer.